What Has Been the Growth of the Cancer Biologics Market So Far?
The cancer biologics market has seen considerable growth due to a variety of factors.
• In the last few years, there has been a substantial expansion in the size of the cancer biologics market. It is anticipated to grow from $106.2 billion in 2024 to $117.03 billion in 2025, seeing a compound annual growth rate (CAGR) of 10.2%.
Factors such as a rise in the occurrence of cancer, heightened awareness surrounding cancer biologics, enhanced efficacy and safety, approval of new cancer biologic treatments, and a growing preference towards combination therapy have contributed to historical growth patterns.
What Are the Future Growth Projections for the Cancer Biologics Market?
The cancer biologics market is expected to maintain its strong growth trajectory in upcoming years.
• Over the coming years, the cancer biologics market is projected to experience significant expansion, reaching a value of $168.75 billion in 2029 with a compound annual growth rate (CAGR) of 9.6%.
This anticipated growth during the forecast period is largely due to factors such as the broadening of indications, the introduction of combination therapies, the use of real-world evidence, and the development of gene and cell therapies. The period is also expected to showcase predominant trends such as the progress in biotechnology, individualized cancer biologics, biobetters, biosimilars, enhancements in patient support services, and the rise in companion diagnostics.
What Are The Core Factors Supporting Growth In The Cancer Biologics Market?
The escalating occurrence of chronic ailments is a prominent factor contributing to the growth of the cancer biologics market. Chronic diseases are enduring health conditions that compromise the wellbeing of disabled individuals, and cancer sits amongst the most prevalent chronic ailments. Top chronic diseases include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, data released by the Centers for Disease Control and Prevention (CDC), an American public health institution, in February 2024 indicated an upward trend in Americans coping with multiple chronic diseases, with 42% managing at least two, and 12% handling five or more. Hence, the increasing incidence of chronic diseases is predicted to propel the cancer biologics market expansion in the ensuing years.
What Are The Major Segments Within The Global Cancer Biologics Market?
The cancer biologics market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types
2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications
3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines
3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy
4) By Other Types: Cytokines, Growth Factors, Fusion Proteins
Pre-Book The Cancer Biologics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Cancer Biologics Industry?
Firms operating in the cancer biologics sector are advancing predictive biomarkers used by doctors to determine patient treatment plans, by leveraging physiological biomarkers for performance forecasting. Predictive biomarkers investigate tumor advancement in patients by examining the key causal factors, given that each patient's cancer etiology varies. Importantly, these biomarkers contribute not only to the early identification of cancer, but also assist in choosing the most cost-beneficial treatment strategies, particularly for biologics derived from gene therapy.
Who Are the Key Players In The Cancer Biologics Market?
Major companies operating in the cancer biologics market include:
• AbbVie Inc.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• AmgenInc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Merck & Co.Inc.
• Novartis AG
• Pfizer Inc.
• Celgene Corporation
• Daiichi Sankyo Company Ltd.
• Seagen Inc.
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Incyte Corporation
• Karyopharm Therapeutics Inc.
• Kyowa Kirin Co Ltd.
• Ipsen Biopharmaceuticals Inc.
• Bayer AG
• Biocon Limited
• Genentech Inc.
• Gilead Sciences Inc.
• Puma Biotechnology
• Regeneron Pharmaceuticals Inc.
What Is The Most Dominant Region In The Cancer Biologics Market?
North America was the largest region in the cancer biologics market in 2024. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
